Last reviewed · How we verify
OROS-Methylphenidate (MPH)
OROS-Methylphenidate is an extended-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system.
OROS-Methylphenidate is an extended-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
At a glance
| Generic name | OROS-Methylphenidate (MPH) |
|---|---|
| Also known as | Concerta |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Drug class | Sympathomimetic amine; central nervous system stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate blocks the reuptake transporters for dopamine and norepinephrine, increasing their synaptic concentrations and enhancing neurotransmission in the prefrontal cortex and striatum. The OROS (osmotic release oral system) delivery mechanism provides controlled, extended release of the drug over approximately 12 hours, maintaining therapeutic levels throughout the day. This sustained-release formulation improves compliance and provides more consistent symptom control compared to immediate-release formulations.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Abdominal pain
- Nervousness
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Benefits of ADHD Treatment in Detained People (PHASE3)
- The Effects of ADHD Medication (TEAM) Study (PHASE4)
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original (NA)
- Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
- Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 (PHASE3)
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (PHASE4)
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |